Kalaris Therapeutics, Inc. (KLRS)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Kalaris Therapeutics, Inc. — S-3 Filing
# 🧾 What This Document Is This is an **S-3 registration statement**, essentially a "permission slip" from the SEC. It allows specific existing shareholders of Kalaris Therapeutics to sell their shares to the public on the open market. Think of it as the company facilitating a secondary sale, not ra
Kalaris Therapeutics, Inc. — S-3 Filing
# 🧾 What This Document Is This is an **S-3 filing** with the SEC, specifically containing an **Indenture** for **subordinated debt securities**. Think of it as the master rulebook the company will follow if it decides to issue corporate bonds (IOUs) to investors in the future. It doesn't issue any
SEC filings
All filings →Insider trades
All insider trades →Kalaris Therapeutics, Inc. has no reported insider trades in the last 90 days.